{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:20:10Z","timestamp":1791422410732,"version":"4.3.3"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/gt.2017.35","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T14:41:06Z","timestamp":1493908866000},"page":"377-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Current application of CRISPR\/Cas9 gene-editing technique to eradication of HIV\/AIDS"],"prefix":"10.1038","volume":"24","author":[{"given":"Z","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tomitaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"BFgt201735_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/387183a0","volume":"387","author":"TW Chun","year":"1997","unstructured":"Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183\u2013188.","journal-title":"Nature"},{"key":"BFgt201735_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1084\/jem.188.1.83","volume":"188","author":"TW Chun","year":"1998","unstructured":"Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS . Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188: 83\u201391.","journal-title":"J Exp Med"},{"key":"BFgt201735_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295\u20131300.","journal-title":"Science"},{"key":"BFgt201735_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nm880","volume":"9","author":"JD Siliciano","year":"2003","unstructured":"Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine 2003; 9: 727\u2013728.","journal-title":"Nature Medicine"},{"key":"BFgt201735_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/00002030-199606000-00002","volume":"10","author":"O Bagasra","year":"1996","unstructured":"Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996; 10: 573\u2013585.","journal-title":"AIDS"},{"key":"BFgt201735_CR6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/135502801753248114","volume":"7","author":"T Fischer-Smith","year":"2001","unstructured":"Fischer-Smith T, Croul S, Sverstiuk AE, Capini C, L'Heureux D, Regulier EG et al. CNS invasion by CD14+\/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 2001; 7: 528\u2013541.","journal-title":"J Neurovirol"},{"key":"BFgt201735_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3109\/13550289909021295","volume":"5","author":"CK Petito","year":"1999","unstructured":"Petito CK, Chen H, Mastri AR, Torres-Munoz J, Roberts B, Wood C . HIV infection of choroid plexus in AIDS and asymptomatic HIV-infected patients suggests that the choroid plexus may be a reservoir of productive infection. J Neurovirol 1999; 5: 670\u2013677.","journal-title":"J Neurovirol"},{"key":"BFgt201735_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1172\/JCI114981","volume":"87","author":"MJ McElrath","year":"1991","unstructured":"McElrath MJ, Steinman RM, Cohn ZA . Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J Clin Invest 1991; 87: 27\u201330.","journal-title":"J Clin Invest"},{"key":"BFgt201735_CR9","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","volume":"95","author":"TW Chun","year":"1998","unstructured":"Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95: 8869\u20138873.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201735_CR10","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1086\/527324","volume":"197","author":"TW Chun","year":"2008","unstructured":"Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197: 714\u2013720.","journal-title":"J Infect Dis"},{"key":"BFgt201735_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1189\/jlb.0503219","volume":"74","author":"PD Smith","year":"2003","unstructured":"Smith PD, Meng G, Salazar-Gonzalez JF, Shaw GM . Macrophage HIV-1 infection and the gastrointestinal tract reservoir. J Leuko Biol 2003; 74: 642\u2013649.","journal-title":"J Leuko Biol"},{"key":"BFgt201735_CR12","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1128\/AAC.00725-10","volume":"54","author":"S Lambert-Niclot","year":"2010","unstructured":"Lambert-Niclot S, Peytavin G, Duvivier C, Poirot C, Algarte-Genin M, Pakianather S et al. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600\/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 2010; 54: 4910\u20134913.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFgt201735_CR13","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1097\/QAD.0b013e32833e5043","volume":"24","author":"S Cu-Uvin","year":"2010","unstructured":"Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24: 2489\u20132497.","journal-title":"AIDS"},{"key":"BFgt201735_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893\u2013900.","journal-title":"Nat Med"},{"key":"BFgt201735_CR15","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1172\/JCI26197","volume":"115","author":"TW Chun","year":"2005","unstructured":"Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115: 3250\u20133255.","journal-title":"J Clin Invest"},{"key":"BFgt201735_CR16","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1073\/pnas.1318249111","volume":"111","author":"CV Fletcher","year":"2014","unstructured":"Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014; 111: 2307\u20132312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201735_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archneurol.2007.31","volume":"65","author":"S Letendre","year":"2008","unstructured":"Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65\u201370.","journal-title":"Arch Neurol"},{"key":"BFgt201735_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1128\/AAC.47.1.238-243.2003","volume":"47","author":"C Solas","year":"2003","unstructured":"Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B . Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 238\u2013243.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFgt201735_CR19","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","volume":"75","author":"RK Heaton","year":"2010","unstructured":"Heaton RK, Clifford DB, Franklin DR Jr., Woods SP, Ake C, Vaida F et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 2087\u20132096.","journal-title":"Neurology"},{"key":"BFgt201735_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/cid\/ciu862","volume":"60","author":"RK Heaton","year":"2015","unstructured":"Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 2015; 60: 473\u2013480.","journal-title":"Clin Infect Dis"},{"key":"BFgt201735_CR21","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789\u20131799.","journal-title":"Neurology"},{"key":"BFgt201735_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ana.21697","volume":"66","author":"MJ Churchill","year":"2009","unstructured":"Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009; 66: 253\u2013258.","journal-title":"Ann Neurol"},{"key":"BFgt201735_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archneurol.2010.76","volume":"67","author":"RJ Ellis","year":"2010","unstructured":"Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010; 67: 552\u2013558.","journal-title":"Arch Neurol"},{"key":"BFgt201735_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/13550280600748946","volume":"12","author":"MJ Churchill","year":"2006","unstructured":"Churchill MJ, Gorry PR, Cowley D, Lal L, Sonza S, Purcell DF et al. Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 2006; 12: 146\u2013152.","journal-title":"J Neurovirol"},{"key":"BFgt201735_CR25","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1128\/JVI.03333-13","volume":"88","author":"SD Narasipura","year":"2014","unstructured":"Narasipura SD, Kim S, Al-Harthi L . Epigenetic regulation of HIV-1 latency in astrocytes. J Virol 2014; 88: 3031\u20133038.","journal-title":"J Virol"},{"key":"BFgt201735_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13365-014-0291-1","volume":"21","author":"A Nath","year":"2015","unstructured":"Nath A . Eradication of human immunodeficiency virus from brain reservoirs. J Neurovirol 2015; 21: 227\u2013234.","journal-title":"J Neurovirol"},{"key":"BFgt201735_CR27","first-page":"pii:00022","volume":"1","author":"W Dampier","year":"2014","unstructured":"Dampier W, Nonnemacher MR, Sullivan NT, Jacobson JM, Wigdahl B . HIV excision utilizing crispr\/cas9 technology: attacking the proviral quasispecies in reservoirs to achieve a cure. MOJ Immunol 2014; 1: pii:00022.","journal-title":"MOJ Immunol"},{"key":"BFgt201735_CR28","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1038\/srep02510","volume":"3","author":"H Ebina","year":"2013","unstructured":"Ebina H, Misawa N, Kanemura Y, Koyanagi Y . Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013; 3: 2510.","journal-title":"Sci Rep"},{"key":"BFgt201735_CR29","doi-asserted-by":"publisher","first-page":"11461","DOI":"10.1073\/pnas.1405186111","volume":"111","author":"W Hu","year":"2014","unstructured":"Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 2014; 111: 11461\u201311466.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201735_CR30","doi-asserted-by":"publisher","first-page":"22555","DOI":"10.1038\/srep22555","volume":"6","author":"R Kaminski","year":"2016","unstructured":"Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y et al. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR\/Cas9 gene editing. Sci Rep 2016; 6: 22555.","journal-title":"Sci Rep"},{"key":"BFgt201735_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/mt.2015.202","volume":"24","author":"SM Saayman","year":"2016","unstructured":"Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC et al. Potent and targeted activation of latent HIV-1 using the CRISPR\/dCas9 activator complex. Mol Ther 2016; 24: 488\u2013498.","journal-title":"Mol Ther"},{"key":"BFgt201735_CR32","doi-asserted-by":"publisher","first-page":"16277","DOI":"10.1038\/srep16277","volume":"5","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Yin C, Zhang T, Li F, Yang W, Kaminski R et al. CRISPR\/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep 2015; 5: 16277.","journal-title":"Sci Rep"},{"key":"BFgt201735_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.4161\/rna.24321","volume":"10","author":"K Chylinski","year":"2013","unstructured":"Chylinski K, Le Rhun A, Charpentier E . The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol 2013; 10: 726\u2013737.","journal-title":"RNA Biol"},{"key":"BFgt201735_CR34","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816\u2013821.","journal-title":"Science"},{"key":"BFgt201735_CR35","doi-asserted-by":"publisher","first-page":"e1004955","DOI":"10.1371\/journal.ppat.1004955","volume":"11","author":"L Chavez","year":"2015","unstructured":"Chavez L, Calvanese V, Verdin E . HIV latency is established directly and early in both resting and activated primary CD4 T cells. PLoS Pathog 2015; 11: e1004955.","journal-title":"PLoS Pathog"},{"key":"BFgt201735_CR36","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1056\/NEJM199605093341903","volume":"334","author":"SK Stanley","year":"1996","unstructured":"Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334: 1222\u20131230.","journal-title":"N Engl J Med"},{"key":"BFgt201735_CR37","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1097\/QAD.0b013e32832caf28","volume":"23","author":"T Brady","year":"2009","unstructured":"Brady T, Agosto LM, Malani N, Berry CC, O'Doherty U, Bushman F . HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009; 23: 1461\u20131471.","journal-title":"AIDS"},{"key":"BFgt201735_CR38","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/QAD.0000000000000691","volume":"29","author":"M Schneider","year":"2015","unstructured":"Schneider M, Tigges B, Meggendorfer M, Helfer M, Ziegenhain C, Brack-Werner R . A new model for post-integration latency in macroglial cells to study HIV-1 reservoirs of the brain. AIDS 2015; 29: 1147\u20131159.","journal-title":"AIDS"},{"key":"BFgt201735_CR39","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1128\/JVI.01617-15","volume":"90","author":"S Sunshine","year":"2016","unstructured":"Sunshine S, Kirchner R, Amr SS, Mansur L, Shakhbatyan R, Kim M et al. HIV Integration site analysis of cellular models of HIV latency with a probe-enriched next-generation sequencing assay. J Virol 2016; 90: 4511\u20134519.","journal-title":"J Virol"},{"key":"BFgt201735_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/sj.emboj.7601517","volume":"26","author":"I du Chene","year":"2007","unstructured":"du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 2007; 26: 424\u2013435.","journal-title":"EMBO J"},{"key":"BFgt201735_CR41","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1128\/JVI.01920-10","volume":"85","author":"E Gallastegui","year":"2011","unstructured":"Gallastegui E, Millan-Zambrano G, Terme JM, Chavez S, Jordan A . Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J Virol 2011; 85: 3187\u20133202.","journal-title":"J Virol"},{"key":"BFgt201735_CR42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1097-2765(01)00314-8","volume":"8","author":"M Barboric","year":"2001","unstructured":"Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM . NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001; 8: 327\u2013337.","journal-title":"Mol Cell"},{"key":"BFgt201735_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.chom.2008.05.016","volume":"4","author":"T Lenasi","year":"2008","unstructured":"Lenasi T, Contreras X, Peterlin BM . Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 2008; 4: 123\u2013133.","journal-title":"Cell Host Microbe"},{"key":"BFgt201735_CR44","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/nm1639","volume":"13","author":"J Huang","year":"2007","unstructured":"Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007; 13: 1241\u20131247.","journal-title":"Nat Med"},{"key":"BFgt201735_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12977-014-0108-6","volume":"11","author":"P Patel","year":"2014","unstructured":"Patel P, Ansari MY, Bapat S, Thakar M, Gangakhedkar R, Jameel S . The microRNA miR-29a is associated with human immunodeficiency virus latency. Retrovirology 2014; 11: 108.","journal-title":"Retrovirology"},{"key":"BFgt201735_CR46","doi-asserted-by":"publisher","first-page":"13736","DOI":"10.1074\/jbc.M115.641837","volume":"290","author":"DS Ruelas","year":"2015","unstructured":"Ruelas DS, Chan JK, Oh E, Heidersbach AJ, Hebbeler AM, Chavez L et al. MicroRNA-155 Reinforces HIV Latency. J Biol Chem 2015; 290: 13736\u201313748.","journal-title":"J Biol Chem"},{"key":"BFgt201735_CR47","first-page":"ofw189","volume":"3","author":"HM Delagreverie","year":"2016","unstructured":"Delagreverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ . Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents. open forum. Infect Dis 2016; 3: ofw189.","journal-title":"Infect Dis"},{"key":"BFgt201735_CR48","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482\u2013485.","journal-title":"Nature"},{"key":"BFgt201735_CR49","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","volume":"1","author":"TA Rasmussen","year":"2014","unstructured":"Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial. Lancet HIV 2014; 1: e13\u2013e21.","journal-title":"Lancet HIV"},{"key":"BFgt201735_CR50","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1126\/science.1078395","volume":"300","author":"MH Porteus","year":"2003","unstructured":"Porteus MH, Baltimore D . Chimeric nucleases stimulate gene targeting in human cells. Science 2003; 300: 763.","journal-title":"Science"},{"key":"BFgt201735_CR51","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt1319","volume":"25","author":"JC Miller","year":"2007","unstructured":"Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 2007; 25: 778\u2013785.","journal-title":"Nat Biotechnol"},{"key":"BFgt201735_CR52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1126\/science.1207773","volume":"333","author":"AJ Wood","year":"2011","unstructured":"Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH et al. Targeted genome editing across species using ZFNs and TALENs. Science 2011; 333: 307.","journal-title":"Science"},{"key":"BFgt201735_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt.1755","volume":"29","author":"JC Miller","year":"2011","unstructured":"Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011; 29: 143\u2013148.","journal-title":"Nat Biotechnol"},{"key":"BFgt201735_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nbt.1775","volume":"29","author":"F Zhang","year":"2011","unstructured":"Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P . Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 2011; 29: 149\u2013153.","journal-title":"Nat Biotechnol"},{"key":"BFgt201735_CR55","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nbt.2170","volume":"30","author":"D Reyon","year":"2012","unstructured":"Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK . FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 2012; 30: 460\u2013465.","journal-title":"Nat Biotechnol"},{"key":"BFgt201735_CR56","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.1138140","volume":"315","author":"R Barrangou","year":"2007","unstructured":"Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007; 315: 1709\u20131712.","journal-title":"Science"},{"key":"BFgt201735_CR57","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 2013; 339: 819\u2013823.","journal-title":"Science"},{"key":"BFgt201735_CR58","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823\u2013826.","journal-title":"Science"},{"key":"BFgt201735_CR59","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F . Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157: 1262\u20131278.","journal-title":"Cell"},{"key":"BFgt201735_CR60","doi-asserted-by":"crossref","unstructured":"Shi B, Li J, Shi X, Jia W, Wen Y, Hu X et al. TALEN-mediated knockout of CCR5 confers protection against infection of human immunodeficiency virus. J Acquir Immune Defic Syndr 2016.","DOI":"10.1097\/QAI.0000000000001190"},{"key":"BFgt201735_CR61","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901\u2013910.","journal-title":"N Engl J Med"},{"key":"BFgt201735_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/hum.2012.172","volume":"24","author":"DA Maier","year":"2013","unstructured":"Maier DA, Brennan AL, Jiang S, Binder-Scholl GK, Lee G, Plesa G et al. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther 2013; 24: 245\u2013258.","journal-title":"Hum Gene Ther"},{"key":"BFgt201735_CR63","doi-asserted-by":"publisher","first-page":"e0125652","DOI":"10.1371\/journal.pone.0125652","volume":"10","author":"CL Strong","year":"2015","unstructured":"Strong CL, Guerra HP, Mathew KR, Roy N, Simpson LR, Schiller MR . Damaging the Integrated HIV Proviral DNA with TALENs. PloS One 2015; 10: e0125652.","journal-title":"PloS One"},{"key":"BFgt201735_CR64","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nature13579","volume":"513","author":"C Anders","year":"2014","unstructured":"Anders C, Niewoehner O, Duerst A, Jinek M . Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 2014; 513: 569\u2013573.","journal-title":"Nature"},{"key":"BFgt201735_CR65","doi-asserted-by":"publisher","first-page":"1247997","DOI":"10.1126\/science.1247997","volume":"343","author":"M Jinek","year":"2014","unstructured":"Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 2014; 343: 1247997.","journal-title":"Science"},{"key":"BFgt201735_CR66","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","volume":"156","author":"H Nishimasu","year":"2014","unstructured":"Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 2014; 156: 935\u2013949.","journal-title":"Cell"},{"key":"BFgt201735_CR67","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F . Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8: 2281\u20132308.","journal-title":"Nat Protoc"},{"key":"BFgt201735_CR68","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015; 517: 583\u2013588.","journal-title":"Nature"},{"key":"BFgt201735_CR69","doi-asserted-by":"publisher","first-page":"15577","DOI":"10.1038\/srep15577","volume":"5","author":"P Hou","year":"2015","unstructured":"Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M et al. Genome editing of CXCR4 by CRISPR\/cas9 confers cells resistant to HIV-1 infection. Sci Rep 2015; 5: 15577.","journal-title":"Sci Rep"},{"key":"BFgt201735_CR70","doi-asserted-by":"publisher","first-page":"10437","DOI":"10.1073\/pnas.1512503112","volume":"112","author":"K Schumann","year":"2015","unstructured":"Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA 2015; 112: 10437\u201310442.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201735_CR71","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1073\/pnas.1407473111","volume":"111","author":"L Ye","year":"2014","unstructured":"Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 2014; 111: 9591\u20139596.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201735_CR72","doi-asserted-by":"publisher","first-page":"e115987","DOI":"10.1371\/journal.pone.0115987","volume":"9","author":"W Wang","year":"2014","unstructured":"Wang W, Ye C, Liu J, Zhang D, Kimata JT, Zhou P . CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PloS One 2014; 9: e115987.","journal-title":"PloS One"},{"key":"BFgt201735_CR73","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1099\/vir.0.000139","volume":"96","author":"C Li","year":"2015","unstructured":"Li C, Guan X, Du T, Jin W, Wu B, Liu Y et al. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9. J Gen Virol 2015; 96: 2381\u20132393.","journal-title":"J Gen Virol"},{"key":"BFgt201735_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12977-015-0150-z","volume":"12","author":"W Zhu","year":"2015","unstructured":"Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA et al. The CRISPR\/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 2015; 12: 22.","journal-title":"Retrovirology"},{"key":"BFgt201735_CR75","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/gt.2016.45","volume":"23","author":"R Kaminski","year":"2016","unstructured":"Kaminski R, Bella R, Yin C, Otte J, Ferrante P, Gendelman HE et al. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther 2016; 23: 696.","journal-title":"Gene Ther"},{"key":"BFgt201735_CR76","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/mt.2016.24","volume":"24","author":"G Wang","year":"2016","unstructured":"Wang G, Zhao N, Berkhout B, Das AT . CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther 2016; 24: 522\u2013526.","journal-title":"Mol Ther"},{"key":"BFgt201735_CR77","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.celrep.2016.03.042","volume":"15","author":"Z Wang","year":"2016","unstructured":"Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S et al. CRISPR\/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep 2016; 15: 481\u2013489.","journal-title":"Cell Rep"},{"key":"BFgt201735_CR78","doi-asserted-by":"publisher","first-page":"29530","DOI":"10.1038\/srep29530","volume":"6","author":"KE Yoder","year":"2016","unstructured":"Yoder KE, Bundschuh R . Host double strand break repair generates hiv-1 strains resistant to CRISPR\/Cas9. Sci Rep 2016; 6: 29530.","journal-title":"Sci Rep"},{"key":"BFgt201735_CR79","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.2951","volume":"32","author":"D Heckl","year":"2014","unstructured":"Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 2014; 32: 941\u2013946.","journal-title":"Nat Biotechnol"},{"key":"BFgt201735_CR80","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014; 159: 440\u2013455.","journal-title":"Cell"},{"key":"BFgt201735_CR81","doi-asserted-by":"publisher","first-page":"11529","DOI":"10.1038\/ncomms11529","volume":"7","author":"M Mansouri","year":"2016","unstructured":"Mansouri M, Bellon-Echeverria I, Rizk A, Ehsaei Z, Cianciolo Cosentino C, Silva CS et al. Highly efficient baculovirus-mediated multigene delivery in primary cells. Nat Commun 2016; 7: 11529.","journal-title":"Nat Commun"},{"key":"BFgt201735_CR82","doi-asserted-by":"publisher","first-page":"7391","DOI":"10.1038\/ncomms8391","volume":"6","author":"M Zuckermann","year":"2015","unstructured":"Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, Zapatka M, Northcott PA, Schramm K et al. Somatic CRISPR\/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun 2015; 6: 7391.","journal-title":"Nat Commun"},{"key":"BFgt201735_CR83","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3109\/1061186X.2015.1025077","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Hao Y, Li H, Zhao Y, Meng D, Li D et al. Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles. J Drug Target 2015; 23: 832\u2013846.","journal-title":"J Drug Target"},{"key":"BFgt201735_CR84","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1073\/pnas.1520244113","volume":"113","author":"M Wang","year":"2016","unstructured":"Wang M, Zuris JA, Meng F, Rees H, Sun S, Deng P et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci USA 2016; 113: 2868\u20132873.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201735_CR85","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1021\/acs.molpharmaceut.5b00822","volume":"13","author":"S Qazi","year":"2016","unstructured":"Qazi S, Miettinen HM, Wilkinson RA, McCoy K, Douglas T, Wiedenheft B . Programmed self-assembly of an active P22-Cas9 nanocarrier system. Mol Pharm 2016; 13: 1191\u20131196.","journal-title":"Mol Pharm"},{"key":"BFgt201735_CR86","doi-asserted-by":"publisher","first-page":"12029","DOI":"10.1002\/anie.201506030","volume":"54","author":"W Sun","year":"2015","unstructured":"Sun W, Ji W, Hall JM, Hu Q, Wang C, Beisel CL et al. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed Engl 2015; 54: 12029\u201312033.","journal-title":"Angew Chem Int Ed Engl"},{"key":"BFgt201735_CR87","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.3471","volume":"34","author":"H Yin","year":"2016","unstructured":"Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 2016; 34: 328\u2013333.","journal-title":"Nat Biotechnol"},{"key":"BFgt201735_CR88","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1177\/42.11.7930531","volume":"42","author":"U Bickel","year":"1994","unstructured":"Bickel U, Kang YS, Yoshikawa T, Pardridge WM . In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem 1994; 42: 1493\u20131497.","journal-title":"J Histochem Cytochem"},{"key":"BFgt201735_CR89","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0022-3565(25)10429-1","volume":"263","author":"T Yoshikawa","year":"1992","unstructured":"Yoshikawa T, Pardridge WM . Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J Pharmacol Exp Ther 1992; 263: 897\u2013903.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFgt201735_CR90","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/jgm.449","volume":"5","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Boado RJ, Pardridge WM . In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 2003; 5: 1039\u20131045.","journal-title":"J Gene Med"},{"key":"BFgt201735_CR91","doi-asserted-by":"publisher","first-page":"12486","DOI":"10.1073\/pnas.1517048112","volume":"112","author":"AJ Clark","year":"2015","unstructured":"Clark AJ, Davis ME . Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc Natl Acad Sci USA 2015; 112: 12486\u201312491.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201735_CR92","doi-asserted-by":"publisher","first-page":"055101","DOI":"10.1088\/0957-4484\/25\/5\/055101","volume":"25","author":"H Ding","year":"2014","unstructured":"Ding H, Sagar V, Agudelo M, Pilakka-Kanthikeel S, Atluri VS, Raymond A et al. Enhanced blood-brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology 2014; 25: 055101.","journal-title":"Nanotechnology"},{"key":"BFgt201735_CR93","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijpharm.2014.12.057","volume":"479","author":"MA De Luca","year":"2015","unstructured":"De Luca MA, Lai F, Corrias F, Caboni P, Bimpisidis Z, Maccioni E et al. Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation. Int J Pharm 2015; 479: 129\u2013137.","journal-title":"Int J Pharm"},{"key":"BFgt201735_CR94","doi-asserted-by":"publisher","first-page":"16890","DOI":"10.1039\/C5NR02831K","volume":"7","author":"A Tomitaka","year":"2015","unstructured":"Tomitaka A, Arami H, Gandhi S, Krishnan KM . Lactoferrin conjugated iron oxide nanoparticles for targeting brain glioma cells in magnetic particle imaging. Nanoscale 2015; 7: 16890\u201316898.","journal-title":"Nanoscale"},{"key":"BFgt201735_CR95","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jconrel.2015.06.002","volume":"211","author":"C Fornaguera","year":"2015","unstructured":"Fornaguera C, Dols-Perez A, Caldero G, Garcia-Celma MJ, Camarasa J, Solans C . PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier. J Control Release 2015; 211: 134\u2013143.","journal-title":"J Control Release"},{"key":"BFgt201735_CR96","doi-asserted-by":"publisher","first-page":"11336","DOI":"10.1021\/acsami.6b02838","volume":"8","author":"Y Huang","year":"2016","unstructured":"Huang Y, Zhang B, Xie S, Yang B, Xu Q, Tan J et al. Modified with Tween 80 pass through the intact blood-brain barrier in rats under magnetic field. ACS Appl Mater Interfaces 2016; 8: 11336\u201311341.","journal-title":"ACS Appl Mater Interfaces"},{"key":"BFgt201735_CR97","doi-asserted-by":"publisher","first-page":"25309","DOI":"10.1038\/srep25309","volume":"6","author":"A Kaushik","year":"2016","unstructured":"Kaushik A, Jayant RD, Nikkhah-Moshaie R, Bhardwaj V, Roy U, Huang Z et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci Rep 2016; 6: 25309.","journal-title":"Sci Rep"},{"key":"BFgt201735_CR98","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/ncomms2717","volume":"4","author":"M Nair","year":"2013","unstructured":"Nair M, Guduru R, Liang P, Hong J, Sagar V, Khizroev S . Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun 2013; 4: 1707.","journal-title":"Nat Commun"},{"key":"BFgt201735_CR99","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1166\/jbn.2015.2108","volume":"11","author":"V Sagar","year":"2015","unstructured":"Sagar V, Pilakka-Kanthikeel S, Atluri VS, Ding H, Arias AY, Jayant RD et al. Therapeutical neurotargeting via magnetic nanocarrier: implications to opiate-induced neuropathogenesis and neuroAIDS. J Biomed Nanotechnol 2015; 11: 1722\u20131733.","journal-title":"J Biomed Nanotechnol"},{"key":"BFgt201735_CR100","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2147\/IJN.S76517","volume":"10","author":"RD Jayant","year":"2015","unstructured":"Jayant RD, Atluri VS, Agudelo M, Sagar V, Kaushik A, Nair M . Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomed 2015; 10: 1077\u20131093.","journal-title":"Int J Nanomed"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201735.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201735","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/gt.2017.35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/gt201735.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:08:40Z","timestamp":1750223320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFgt201735"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.35","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]},"assertion":[{"value":"25 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}